FDA-Approved MedicationUpdated November 2026

Saxenda Guide

Saxenda is liraglutide 3.0 mg under its brand name, and it was the first of the GLP-1 receptor agonists to earn an FDA chronic weight management approval in adults (December 23, 2014) and later for adolescents aged 12 and older (December 4, 2020). It is a once-daily subcutaneous injection delivered through a single-patient-use pre-filled pen and is manufactured by Novo Nordisk. The once-weekly drugs that followed it, Wegovy (semaglutide 2.4 mg) in 2021 and Zepbound (tirzepatide) in 2023, have since overtaken it on weight loss. In the head-to-head STEP-8 trial, semaglutide 2.4 mg produced 15.8% mean weight loss versus 6.4% with liraglutide 3.0 mg over 68 weeks. It was the first GLP-1 approved for weight management in adolescents (12 and older, December 2020); Wegovy injection followed in December 2022. Novo Nordisk is discontinuing Saxenda: the FDA drug shortage list says it will be available until January 2027.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

At a Glance

Saxenda at a glance
Generic NameLiraglutide
Brand NamesSaxenda
FDA StatusFDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled at BMI ≥30, or ≥27 with a comorbidity) (December 23, 2014); pediatric indication for patients aged 12 years and older with body weight greater than 60 kg and obesity added December 4, 2020. Being discontinued by Novo Nordisk: FDA's drug shortage database lists Saxenda as 'Limited Availability' and says 'Product will be available until discontinuation in January 2027' (reason: discontinuation of manufacture, posted August 25, 2026).[1]
Approval DateDecember 23, 2014[1]

How does Saxenda work?

Liraglutide is an acylated, 97%-homologous analog of native human GLP-1, modified with a fatty-acid side chain that lets it bind albumin and resist DPP-4 degradation — extending its half-life from minutes to about 13 hours. Activating GLP-1 receptors in hypothalamic appetite centers reduces hunger and increases satiety, while peripheral effects slow gastric emptying and dampen meal-time glucose excursions. Paired with increased physical activity and a diet reduced in calories, the net result is that patients eat less and keep weight off.[2]

Dosing Schedule

Saxenda uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Week 10.6mg/day
Week 21.2mg/day
Week 31.8mg/day
Week 42.4mg/day
Week 5+3.0mg/day (maintenance)

What side effects does Saxenda cause?

Common (≥5%): nausea, hypoglycemia (in patients with type 2 diabetes), diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, injection-site reactions. About 9.8% of adult trial patients discontinued for adverse reactions, most commonly nausea (2.9%), vomiting (1.7%), and diarrhea (1.4%). Serious (rare): acute pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury from volume depletion, hypoglycemia (especially when combined with insulin or sulfonylureas), increased heart rate, and serious hypersensitivity reactions including anaphylaxis and angioedema. Boxed warning: liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents; relevance to humans is unknown. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]

Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].

Clinical Trial Results

The pivotal trial was SCALE Obesity and Prediabetes (N=3,731 adults, none diabetic; Pi-Sunyer et al. NEJM 2015, PMID 26132939). At 56 weeks Saxenda 3.0 mg had produced mean body-weight loss of 8.4 kg against 2.8 kg on placebo, and 63.2% of treated patients were past the 5% bar against 27.1% on placebo. A second trial, SCALE Sleep Apnea (Blackman et al. 2016, PMID 27005405), showed significantly greater reductions in apnea-hypopnea index alongside weight loss in adults with moderate-to-severe OSA. The SCALE Teens trial (Kelly et al. NEJM 2020, PMID 32233338) supported the December 2020 adolescent (ages 12+) indication, showing reductions in BMI standard deviation score versus placebo over 56 weeks.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where can you get Saxenda?

Sellers in our register that will dispense liraglutide, or a compounded version of it, after an online consultation — shipped to your door.

5.2/ 10

Cost Plus Drugs

Best for: seeing the manufacturer cost behind the price you pay

★★★☆☆5.2/10

Editorial score · methodology

$716.50/mo
BrandLiraglutide
Get StartedRead full Cost Plus Drugs review →

1 seller in the register publishes a price; the lowest starts at $716.50 a month, checked November 2026. What each one charges to start, cheapest at the top. Compounded liraglutide from state-licensed 503A pharmacies is legal under federal compounding law when made for an individual patient[3], and the rules loosen further, to include bulk compounding by 503B outsourcing facilities, only while a molecule sits on the FDA Drug Shortage List[4]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[5]. What you actually pay moves with your dose and with whatever promotion happens to be running.

Starting Saxenda price per seller, cheapest first. Prices in USD per month; checked November 2026.
ProviderStarting PriceLink
Cost Plus Drugs$716.50/moVisit

Short verdict pages setting Saxenda against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.

See all drug-vs-drug verdicts.

The trials that produced the Saxenda label, taken endpoint by endpoint, with the figures read off the source.

LEADER
LEADER was the first trial to show a GLP-1 reducing cardiovascular events, and everything the class now claims about the heart traces back to it. In 9,340 people whose type 2 diabetes came with established heart disease or high risk, tracked for a median 3.8 years, MACE occurred in 13.0% on liraglutide against 14.9% on placebo. The drug it tested is now commercially overtaken, but the finding shaped how every GLP-1 after it was developed and judged.
Phase 3b/4 · N=9,340
SCALE Teens
SCALE Teens tested liraglutide 3.0 mg in 251 adolescents aged 12 to 17 with obesity, over 56 weeks. BMI standard-deviation score, the measure used in growing bodies where raw BMI moves with development, fell 0.23 against essentially no change on placebo. It supported the 2020 extension of Saxenda's label down to age 12 and was among the first trials to take adolescent obesity pharmacotherapy seriously.
Phase 3 · N=251
SCALE Maintenance
SCALE Maintenance tested whether a GLP-1 helps people keep weight they have already lost. All 422 participants completed a low-calorie diet run-in first, then were randomized. Over 56 weeks the liraglutide arm lost a further 6.2% while the placebo arm lost 0.2%. It is an early version of the question STEP-4 later answered more sharply, and it points the same way.
Phase 3 · N=422
SCALE Diabetes
SCALE Diabetes tested liraglutide 3.0 mg and 1.8 mg in 846 adults with obesity and type 2 diabetes over 56 weeks. The 3.0 mg arm reached −6.0% body weight against −2.0% on placebo, with 1.8 mg landing in between at −4.7%. It established the indication Saxenda still holds in this population, and it is a clear illustration of the dose-response relationship that runs through this whole class.
Phase 3 · N=846

One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.

The peer-reviewed studies on Saxenda and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.

Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.

Generic GLP-1s: Eleven for Liraglutide, and None You Can Buy for Semaglutide
Liraglutide has eleven approved generics cleared for marketing. Semaglutide has one application, tentatively approved, which in FDA’s own words does not allow it to be sold. Tirzepatide has none.
6 min read6 citations
Mounjaro Alternatives: What Costs Less and What You Give Up
Zepbound is the same drug as Mounjaro and costs $299 to $449 a month self-pay against $499. Ozempic, Trulicity, oral semaglutide and generic liraglutide cost less but did less in head-to-head trials. Compounded tirzepatide, SGLT2s and metformin.
11 min read27 citations
Which Drugs Are GLP-1s? Mounjaro, Trulicity, Phentermine and 25 More, Checked
Ozempic, Wegovy, Rybelsus, Trulicity and Foundayo are GLP-1 receptor agonists; Mounjaro and Zepbound add GIP. Phentermine, Contrave, metformin, Jardiance, Januvia and insulin are not. 28 drugs sorted by what each FDA label calls them.
10 min read33 citations
TRICARE, FEHB and PSHB: Who Covers Wegovy and Zepbound in 2026
TRICARE's weight coverage for Wegovy, Zepbound and Saxenda applies only on Prime, Select and the premium plans, with prior authorization; TRICARE For Life is barred by law. OPM requires every FEHB and PSHB plan to cover a GLP-1, but each plan sets its criteria and tier.
9 min read13 citations
How Long Can Zepbound, Wegovy and Ozempic Be Out of the Fridge?
How long each brand-name GLP-1 can stay unrefrigerated, from the storage section of its FDA label: Zepbound and Mounjaro 21 or 30 days by device, Wegovy 28 or 56, Ozempic 56, Saxenda 30, and the Wegovy pill never refrigerated. Plus freezing, expiry and compounded vials.
8 min read6 citations
How Long Do Zepbound, Wegovy and Other GLP-1s Stay in Your System?
Half-lives and washout times for tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), liraglutide, dulaglutide, orforglipron and investigational retatrutide, from FDA labels and trial data, with what the labels say about stopping before pregnancy or surgery.
7 min read9 citations

Frequently Asked Questions

FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled at BMI ≥30, or ≥27 with a comorbidity) (December 23, 2014); pediatric indication for patients aged 12 years and older with body weight greater than 60 kg and obesity added December 4, 2020. Being discontinued by Novo Nordisk: FDA's drug shortage database lists Saxenda as 'Limited Availability' and says 'Product will be available until discontinuation in January 2027' (reason: discontinuation of manufacture, posted August 25, 2026).
What you pay for Saxenda turns on who is selling it and in what form. Uninsured, the branded product runs roughly $1,000 to $1,600 a month; compounded versions through telehealth sellers usually land between $129 and $400. The table above carries the current figures from our register. Before you commit, check whether a manufacturer savings program applies to you.
Common (≥5%): nausea, hypoglycemia (in patients with type 2 diabetes), diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, injection-site reactions. About 9.8% of adult trial patients discontinued for adverse reactions, most commonly nausea (2.9%), vomiting (1.7%), and diarrhea (1.4%). Serious (rare): acute pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury from volume depletion, hypoglycemia (especially when combined with insulin or sulfonylureas), increased heart rate, and serious hypersensitivity reactions including anaphylaxis and angioedema. Boxed warning: liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents; relevance to humans is unknown. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Saxenda is prescription-only, so someone licensed has to write it — your own doctor, an endocrinologist, or one of the telehealth sellers above. For compounded versions the telehealth route is usually both quicker and cheaper out of pocket than a traditional pharmacy.
Sources & methodology — as of November 2026
  1. 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  3. 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  4. 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  5. 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.